A Study of PF-06700841 to Determine the Beneficial Effect at 16 Weeks and the Safety and Beneficial Effect up to 1 Year in Subjects with Active Psoriatic Arthritis. A Phase 2b, Randomized, Double-Blind,
Placebo-Controlled Study of PF-06700841 to Evaluate the Efficacy at 16 Weeks and to Evaluate the Safety
and Efficacy up to 1 Year in Subjects with Active Psoriatic Arthritis.